Pharma advertisers could face new price disclosure rules across TV and digital ads

The news: Senators Dick Durbin (D-Ill.) and Chuck Grassley (R-Iowa) renewed their push to require drugmakers to disclose list prices in direct-to-consumer (D2C) prescription drug ads, per Durbin’s office. Both called for passage of the bipartisan Drug-price Transparency for Consumers (DTC) Act during a Senate Judiciary Committee hearing on drug pricing this week.

The bill, introduced in January 2025, would require all ads for prescription drugs covered by Medicare or Medicaid to disclose their list prices if they cost at least $35 for a 30-day supply or typical course of treatment. Durbin, who is retiring in January, said he hopes the legislation passes before the end of the year.

Why it matters: Lawmakers and regulators have tried to require price disclosures in drug ads under the first Trump administration and failed. And the DTC Act would cover more ad channels than earlier efforts.

You've read 0 of 2 free articles this month.

Get more articles - create your free account today!